Katherine Zafereo Email

VP Investor Relations & Corporate Communications . Amunix Pharmaceuticals

Current Roles

Employees:
89
Revenue:
$13.8M
About
Amunix is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors. Our goal is to save cancer patientsᅢᄁ¬ツᆲ¬トᄁ lives through the development and commercialization of breakthrough therapies that harness the immune system. We have invented XTEN, a validated therapeutic half-life extension technology. Our current focus is Pro-XTEN, a next-generation protease activated pro-drug platform, which enables selective activation of potent cancer therapies in the tumor microenvironment. This overcomes a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Amunixᅢᄁ¬ツᆲ¬トᄁs two lead programs employ the Pro-XTEN technology to enhance the safety profile of T cell engagers. XPATs (XTENylated Protease-Activated T Cell Engagers) have the potential to make off-the-shelf therapies redirecting T cells to solid tumors a reality. Amunixᅢᄁ¬ツᆲ¬トᄁs robust technology has been validated through multiple collaborations with leading biopharmaceutical companies including Celgene, Genentech, Janssen, Roche, and Bioverativ (now Sanofi). In addition, XTENylated drugs have been dosed in greater than 200 patients with minimal immunogenicity against XTEN. Amunix is currently located in Mountain View, CA but is moving to South San Francisco in 2020.
Amunix Pharmaceuticals Address
2 Tower Pl #1100
Mountain View, CA
United States
Amunix Pharmaceuticals Email

Past Companies

Harbour BioMed US (HBM US)SVP of Finance & Corporate Development
LifeSci Fund Management, LLCHead of Marketing & Investor Relations
KBZEE, LLCConsultant

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.